scispace - formally typeset
J

Jean-Claude Tabet

Researcher at Pierre-and-Marie-Curie University

Publications -  242
Citations -  6461

Jean-Claude Tabet is an academic researcher from Pierre-and-Marie-Curie University. The author has contributed to research in topics: Mass spectrometry & Ion. The author has an hindex of 42, co-authored 237 publications receiving 6106 citations. Previous affiliations of Jean-Claude Tabet include Paris Universitas & Centre national de la recherche scientifique.

Papers
More filters
Journal ArticleDOI

Mass spectrometry for the identification of the discriminating signals from metabolomics: Current status and future trends

TL;DR: This review deals with strengths, limitations and future trends in the identification of signals highlighted by API-MS-based metabolomics, covering the identification process from the determination of the molecular mass and/or its elemental composition to the confirmation of structural hypotheses.
Journal ArticleDOI

Solid Ionic Matrixes for Direct Tissue Analysis and MALDI Imaging

TL;DR: New technical developments for the direct tissue analysis of peptides with ionic liquid made of matrix mixtures and a new outlook on peptide tissue profiling by MS, characterization of compounds from tissue slices, and MALDI-MS high-quality imaging are presented.
Journal ArticleDOI

Modifications of milk constituents during processing: A preliminary benchmarking study

TL;DR: In this article, protein and lipid modifications of several infant formulas, as well as pasteurized and UHT milk samples were evaluated, and the levels of secondary lipid oxidation products (malondialdehyde and hexanal), proteins modified by early (furosine, measurement of protein glycation) and advanced (carboxymethyllysine) Maillard reactions, and oxidized and crosslinked proteins (protein carbonyls, dityrosine, lysinoalanine) were measured.
Journal ArticleDOI

Immunopurification and mass spectrometric quantification of the active form of a chimeric therapeutic antibody in human serum.

TL;DR: Liquid chromatography coupled with tandem mass spectrometry provides a sensitive, specific, and accurate absolute quantification of Erbitux, a human:murine chimeric mAb used for the treatment of colorectal cancer and is a potential alternative for pharmacokinetic evaluation of mAbs during clinical development.